Skip to main content
. 2017 Mar 28;8:495. doi: 10.3389/fmicb.2017.00495

Figure 2.

Figure 2

Illustration showing the production route of hybridoma technology. Monoclonal antibodies are generated by immunizing laboratory animals with a target antigen. B cells and myeloma cells are fused and then selected in HAT medium. Finally, hybridoma cells producing the desired antibodies are screened.